The invention relates to the use of various extracts of the Nephelium lappaceum plant for increasing the firmness and/or elasticity of the skin and/or mucous membranes, by increasing type I and/or type V collagen and/or LOX-L, fibulin-5, emiline-1 and/or fibrillin-1 gene and/or protein expression, and/or by decreasing CYR61 expression, in the skin and mucous membranes. Another subject of the invention relates to the use of said extracts in a cosmetic composition comprising at least one cosmetically acceptable excipient. Another subject further relates to a cosmetic care method comprising the application of the extract according to the invention or of a cosmetic composition comprising it, for increasing the firmness and/or elasticity of the skin and/or mucous membranes, by increasing type I and/or type V collagen, fibrillin-1 and/or LOX-L, fibulin-5, emiline-1 and/or fibrillin-1 gene and/or protein expression, and/or by decreasing CYR61 expression, in the skin and mucous membranes. A final subject relates to an N. lappaceum extract for use thereof, alone or in a dermatological or pharmaceutical composition, in the prevention and/or treatment of pathological conditions involving a loss of collagen protein and/or gene expression and/or a pathological loss of firmness of the skin and/or mucus membranes, such as rosacea and telangiectasia.

The present invention provides a composition comprising (i) about 0.05 to about 0.5% by weight retinol; (ii) a polar emollient selected from the group consisting of propylene glycol stearyl ether dicaprylyl carbonate, propylene glycol isostearate and combinations thereof; and (iii) isohexadecane, wherein the weight ratio of polar emollient to isohexadecane is 1:1 or lower and the composition is anhydrous.

The present invention provides a composition comprising (i) about 0.05 to about 0.5% by weight retinol; (ii) a polar emollient selected from the group consisting of propylene glycol stearyl ether dicaprylyl carbonate, propylene glycol isostearate and combinations thereof; and (iii) isohexadecane, wherein the weight ratio of polar emollient to isohexadecane is 1:1 or lower and the composition is anhydrous.

The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.

The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.

A compound of the formula I, wherein the symbols are as defined in the remaining specification, or a mixture of two or more compounds of the formula I, for use as active ingredient in the therapeuticincluding prophylactictreatment of a warm-blooded animal for the regulation of body weight (preferred) and/or fat loss (preferred) and/or for the management of obesity and/or for improving the total cholesterol HDL/LDL ratio; where the compound(s) of the formula I may be present in free form, in the form of a pharmaceutically and/or nutraceutically acceptable salt, in the form of tautomers, in the form of esters and/or in the form of solvates, as well as related invention embodiments.

##STR00001##

A compound of the formula I, wherein the symbols are as defined in the remaining specification, or a mixture of two or more compounds of the formula I, for use as active ingredient in the therapeuticincluding prophylactictreatment of a warm-blooded animal for the regulation of body weight (preferred) and/or fat loss (preferred) and/or for the management of obesity and/or for improving the total cholesterol HDL/LDL ratio; where the compound(s) of the formula I may be present in free form, in the form of a pharmaceutically and/or nutraceutically acceptable salt, in the form of tautomers, in the form of esters and/or in the form of solvates, as well as related invention embodiments.

##STR00001##

A peptide has the formula (I) R.sub.1W.sub.mX.sub.n-AA.sub.1-AA.sub.2-AA.sub.3-Y.sub.pZ.sub.qR.sub.2, where AA.sub.1 is Tyr or Trp, AA.sub.2 is Val, Ile, Leu or Met, AA.sub.3 is Tyr, Phe or Trp, W, X, Y and Z are amino acids, m, n, p and q are each 0 or 1, and m+n+p+q is less than or equal to 2. R.sub.1 is H, a polymer derived from polyethylene glycol, a non-cyclic aliphatic group, alicyclyl, heterocyclyl, heteroarylalkyl, aryl, aralkyl, or R.sub.5CO. R.sub.5 is H, a non-cyclic aliphatic group, alicyclyl, aryl, aralkyl, heterocyclyl or heteroarylalkyl. R.sub.2 is NR.sub.3R.sub.4, OR.sub.3, or SR.sub.3. R.sub.3 and R.sub.4 are each H, a polymer derived from polyethylene glycol, a non-cyclic aliphatic group, alicyclyl, heterocyclyl, heteroarylalkyl, aryl, or aralkyl. R.sub.1 and R.sub.2 are not amino acids. Cosmetic or pharmaceutical compositions may include the peptide. It find use in reduction of lipid accumulation in the skin, treatment of cellulite, and treatment of symptoms of skin aging.

The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules, including cells present in vivo. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.

The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules, including cells present in vivo. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.